KRYSTAL BIOTECH INC COM (USA)
Reported by Hood River Capital Management LLC
Reported 495,586 shares, up 37,073 (8.1%) from the prior quarter.
Reported value 55.0%; share count 8.1% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2021-09-30 | 11794000 |
| 2021-12-31 | 15790000 |
| 2022-03-31 | 25605000 |
| 2022-06-30 | 26856000 |
| 2022-09-30 | 29048000 |
| 2022-12-31 | 33817354 |
| 2023-03-31 | 35818000 |
| 2023-06-30 | 53118000 |
| 2023-09-30 | 53416724 |
| 2023-12-31 | 56883123 |
| 2024-03-31 | 88179617 |
| 2024-06-30 | 95693519 |
| 2024-09-30 | 91397991 |
| 2024-12-31 | 80323655 |
| 2025-03-31 | 94593313 |
| 2025-06-30 | 73269342 |
| 2025-09-30 | 107144177 |
| 2025-12-31 | 151203475 |
| 2026-03-31 | 160051456 |
| 2026-06-30 | 246556586 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q2 2026 | Added | 663,375 | +43,789 (7.1%) | 1.79% | $246,556,586 | 2026-08-14 | |
| Q1 2026 | Added | 619,586 | +6,284 (1.0%) | 1.6% | $160,051,456 | 2026-05-15 | |
| Q4 2025 | Added | 613,302 | +6,356 (1.0%) | 1.66% | $151,203,475 | 2026-02-17 | |
| Q3 2025 | Added | 606,946 | +73,923 (13.9%) | 1.27% | $107,144,177 | 2025-11-14 | |
| Q2 2025 | Added | 533,023 | +8,379 (1.6%) | 1.02% | $73,269,342 | 2025-08-14 | |
| Q1 2025 | Added | 524,644 | +11,918 (2.3%) | 1.61% | $94,593,313 | 2025-05-15 | |
| Q4 2024 | Added | 512,726 | +10,622 (2.1%) | 1.19% | $80,323,655 | 2025-02-14 | |
| Q3 2024 | Reduced | 502,104 | -18,989 (-3.6%) | 1.48% | $91,397,991 | 2024-11-14 | |
| Q2 2024 | Added | 521,093 | +25,507 (5.1%) | 1.98% | $95,693,519 | 2024-08-14 | |
| Q1 2024 | Added | 495,586 | +37,073 (8.1%) | 1.97% | $88,179,617 | 2024-05-15 | |
| Q4 2023 | Reduced | 458,513 | -1,976 (-0.4%) | 1.56% | $56,883,123 | 2024-02-14 | |
| Q3 2023 | Added | 460,489 | +8,033 (1.8%) | 1.71% | $53,416,724 | 2023-11-14 | |
| Q2 2023 | Added | 452,456 | +5,063 (1.1%) | 1.58% | $53,118,000 | 2023-08-14 | |
| Q1 2023 | Added | 447,393 | +20,514 (4.8%) | 1.16% | $35,818,000 | 2023-05-15 | |
| Q4 2022 | Added | 426,879 | +10,123 (2.4%) | 1.23% | $33,817,354 | 2023-02-14 | |
| Q3 2022 | Added | 416,756 | +7,745 (1.9%) | 1.11% | $29,048,000 | 2022-11-14 | |
| Q2 2022 | Added | 409,011 | +24,201 (6.3%) | 1.07% | $26,856,000 | 2022-08-15 | |
| Q1 2022 | Added | 384,810 | +159,083 (70.5%) | 0.85% | $25,605,000 | 2022-05-16 | |
| Q4 2021 | Reduced | 225,727 | -174 (-0.1%) | 0.47% | $15,790,000 | 2022-02-14 | |
| Q3 2021 | Reduced | 225,901 | -8,866 (-3.8%) | 0.36% | $11,794,000 | 2021-11-15 | |
|
Five years are shown. A free account unlocks the complete reported history.
Unlock full history
|
|||||||
Who else reported the position
262 managers reported KRYSTAL BIOTECH INC COM (USA) for Q1 2024.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| FMR LLC | Added | 4,243,892 | +1,857,994 | 0.05% | $755,115,704 | 27 qtrs |
| Avoro Capital Advisors LLC | Reduced | 2,555,555 | -10,000 | 5.3% | $454,709,901 | 10 qtrs |
| VANGUARD GROUP INC | Reduced | 2,432,779 | -2,995 | < 0.01% | $432,864,367 | 26 qtrs |
| BlackRock Inc | Reduced | 1,805,379 | -4,168 | < 0.01% | $321,231,085 | 26 qtrs |
| Redmile Group LLC | Reduced | 1,508,250 | -224,939 | 9.85% | $268,362,923 | 22 qtrs |
| Frazier Life Sciences Management L P | Unchanged | 988,460 | 0 | 7.42% | $175,876,688 | 9 qtrs |
| STATE STREET CORPORATION | Reduced | 944,547 | -292,950 | < 0.01% | $168,063,248 | 21 qtrs |
| JENNISON ASSOCIATES LLC | Reduced | 670,735 | -53,609 | 0.08% | $119,343,880 | 4 qtrs |
| PRICE T ROWE ASSOCIATES INC MD | Added | 658,618 | +231,255 | 0.01% | $117,189,000 | 22 qtrs |
| DIMENSIONAL FUND ADVISORS LP | Added | 572,915 | +22,109 | 0.03% | $101,938,767 | 16 qtrs |
Filing details and methodology As reported
- Report period
- March 31, 2024
- Filed
- May 15, 2024
- Filing type
- 13F-HR
- Position type
- COMMON STOCKS
Voting authority reported
- Sole
- 470,344
- Shared
- 0
- None
- 25,242
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.